Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
Main Authors: | Bordi, Paola, Tiseo, Marcello, Baldari, Giorgio, Buti, Sebastiano |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983020/ |
Similar Items
-
Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
by: Morel, Armand, et al.
Published: (2010) -
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†
by: De Santis, M., et al.
Published: (2016) -
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
by: Facchini, Gaetano, et al.
Published: (2016) -
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience
by: Retz, Margitta, et al.
Published: (2015) -
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
by: Médioni, Jacques, et al.
Published: (2016)